Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
34.17
-1.43 (-4.02%)
At close: Oct 16, 2025, 4:00 PM EDT
32.64
-1.53 (-4.48%)
Pre-market: Oct 17, 2025, 8:01 AM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Stoke Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.83, which forecasts a -9.77% decrease in the stock price over the next year. The lowest target is $22 and the highest is $39.
Price Target: $30.83 (-9.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $28 → $39 | Strong Buy | Maintains | $28 → $39 | +14.14% | Oct 13, 2025 |
| Needham | Needham | Strong Buy Maintains $22 → $35 | Strong Buy | Maintains | $22 → $35 | +2.43% | Oct 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | -29.76% | Aug 13, 2025 |
| Wedbush | Wedbush | Buy Maintains $16 → $22 | Buy | Maintains | $16 → $22 | -35.62% | Aug 13, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | -12.20% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
188.82M
from 36.56M
Increased by 416.54%
Revenue Next Year
32.26M
from 188.82M
Decreased by -82.92%
EPS This Year
0.30
from -1.65
EPS Next Year
-2.88
from 0.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 216.1M | 73.5M | |||
| Avg | 188.8M | 32.3M | |||
| Low | 174.8M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 491.1% | -61.1% | |||
| Avg | 416.5% | -82.9% | |||
| Low | 378.2% | -93.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.45 | -2.39 | |||
| Avg | 0.30 | -2.88 | |||
| Low | -0.10 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.